

Jennifer L Clarke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6249957/publications.pdf>

Version: 2024-02-01

74
papers

3,707
citations

236612

25
h-index

143772

57
g-index

75
all docs

75
docs citations

75
times ranked

5844
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
2	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
3	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. <i>Acta Neuropathologica</i> , 2017, 133, 1001-1016.	3.9	245
4	Recent Advances in Therapy for Glioblastoma. <i>Archives of Neurology</i> , 2010, 67, 279-83.	4.9	234
5	Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 241-246.	2.0	148
6	The genetic landscape of ganglioglioma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 47.	2.4	130
7	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
8	External Validation of the ICH Score. <i>Neurocritical Care</i> , 2004, 1, 53-60.	1.2	123
9	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	3.2	112
10	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 1118-1124.	0.6	100
11	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 477-483.	1.4	82
12	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	3.2	68
13	Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. <i>Brain Tumor Research and Treatment</i> , 2017, 5, 1.	0.4	67
14	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	3.9	57
15	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. <i>Neuro-Oncology</i> , 2020, 22, 1580-1590.	0.6	55
16	Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. <i>Neuro-Oncology</i> , 2017, 19, 78-88.	0.6	51
17	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	0.6	48
18	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. <i>Journal of Neuro-Oncology</i> , 2016, 126, 193-200.	1.4	45

#	ARTICLE	IF	CITATIONS
19	Phase II trial of 7 days on/7 days off temozolamide for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 1255-1262.	0.6	44
20	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. <i>Cancer</i> , 2017, 123, 4631-4639.	2.0	43
21	Characterization of serial hyperpolarized ¹³ C metabolic imaging in patients with glioma. <i>NeuroImage: Clinical</i> , 2020, 27, 102323.	1.4	42
22	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 797-804.	0.4	40
23	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020, 8, 151.	2.4	35
24	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.4	35
25	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	0.6	33
26	A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 603-610.	1.1	32
27	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	32
28	Current Advances in Immunotherapy for Glioblastoma. <i>Current Oncology Reports</i> , 2021, 23, 21.	1.8	26
29	Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 868-877.	1.9	25
30	Neuroimaging. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 26-31.	1.0	24
31	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 130, 171-179.	1.4	24
32	Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	22
33	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 877-881.	3.9	21
34	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	3.2	20
35	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	0.6	17
36	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. <i>Neurosurgery</i> , 2022, 90, 124-130.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. <i>Case Reports in Radiology</i> , 2015, 2015, 1-4.	0.5	16
38	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 364-374.	1.0	16
39	Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to "Polymorphous low-grade neuroepithelial tumor of the young"™. <i>Acta Neuropathologica</i> , 2021, 142, 595-599.	3.9	16
40	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. <i>Journal of Neuro-Oncology</i> , 2020, 148, 131-139.	1.4	15
41	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. <i>Neuro-Oncology</i> , 2022, 24, 1471-1481.	0.6	14
42	Case-Based Review: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 106-121.	1.0	13
43	A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma. <i>Journal of Neurosurgery: Spine</i> , 2021, 35, 834-843.	0.9	13
44	Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. <i>Biomedicines</i> , 2016, 4, 24.	1.4	12
45	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. <i>Neuro-Oncology</i> , 2021, 23, 1974-1976.	0.6	12
46	Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. <i>Journal of the National Cancer Institute</i> , 2022, 114, 446-457.	3.0	11
47	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. <i>Acta Neuropathologica</i> , 2022, 143, 109-113.	3.9	11
48	Survivorship care planning in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018, 5, 3-9.	1.0	10
49	Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	0.6	10
50	Standardization and Quality Assurance of Radiation Therapy Volumes for Adults With High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 259-264.	1.0	7
51	Pre-surgery immune profiles of adult glioma patients. <i>Journal of Neuro-Oncology</i> , 2022, 159, 103-115.	1.4	7
52	Case-Based Review: meningioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 120-134.	1.0	6
53	A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. <i>Neuro-Oncology Practice</i> , 2020, 7, 376-383.	1.0	6
54	A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 447-454.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Attitudes toward fertility and fertility preservation in women with glioma. <i>Neuro-Oncology Practice</i> , 2019, 6, 218-225.	1.0	5
56	Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 71-78.	1.4	5
57	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. <i>Translational Oncology</i> , 2015, 8, 446-455.	1.7	3
58	Bevacizumab and Other Targeted Agents in the Upfront Treatment of Glioblastoma. <i>Seminars in Radiation Oncology</i> , 2014, 24, 273-278.	1.0	2
59	PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii166-ii166.	0.6	2
60	RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION. <i>Neuro-Oncology</i> , 2020, 22, ii194-ii194.	0.6	2
61	NCOG-21. INTERIM RESULTS OF THREE COGNITIVE REHABILITATION STRATEGIES IN PATIENTS WITH LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii133-ii134.	0.6	2
62	QOLP-12. EMBEDDING OUTPATIENT PALLIATIVE CARE INTO NEURO-ONCOLOGY CLINIC " RESULTS FROM A ONE YEAR PILOT. <i>Neuro-Oncology</i> , 2020, 22, ii177-ii177.	0.6	1
63	NIMG-50. INITIAL EXPERIENCE: DETECTION OF ABERRANT HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GBM PRIOR TO RESECTION. <i>Neuro-Oncology</i> , 2020, 22, ii159-ii159.	0.6	1
64	ACTR-32. A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi8-vi9.	0.6	0
65	BIOM-13. DNA METHYLATION MARKS GLUCOCORTICOID PATHWAY RESPONSE IN DEXAMETHASONE-TREATED BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii4-ii4.	0.6	0
66	EPID-08. PRE-SURGERY IMMUNE PROFILES OF ADULT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii79-ii80.	0.6	0
67	SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii206-ii206.	0.6	0
68	EPCO-25. AN IMMUNOMETHYLOMIC PLATFORM INTEGRATING SYSTEMIC IMMUNE PROFILES AND EPIGENETIC AGE IN NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , 2020, 22, ii74-ii74.	0.6	0
69	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii138-ii139.	0.6	0
70	PATH-22. COMPREHENSIVE ANALYSIS OF DIVERSE LOW-GRADE NEUROEPITHELIAL TUMORS WITH FGFR1 ALTERATIONS REVEALS A DISTINCT MOLECULAR SIGNATURE OF ROSETTE-FORMING GLIONEURONAL TUMOR. <i>Neuro-Oncology</i> , 2020, 22, ii168-ii169.	0.6	0
71	BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii9-ii10.	0.6	0
72	PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS. <i>Neuro-Oncology</i> , 2020, 22, ii170-ii171.	0.6	0

#	ARTICLE	IF	CITATIONS
73	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii40.	0.6	0
74	SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii207-ii207.	0.6	0